Antimicrobial resistance is one of the most pressing global health challenges, with many antibiotics succumbing to resistance within a decade of clinical use. However, nitrofurantoin, a staple for treating urinary tract infections (UTIs) since the 1950s, counters this trend. Despite its widespread use, resistance to nitrofurantoin remains exceptionally low. A Manchester-based team, led by Dr Danna Gifford<\/a> (EIGen) and involving Dr Mato Lagator<\/a> (EIGen) and Professor Tim Felton<\/a> (DIIRM and MFT), has recently explored the factors behind this durability and what it can teach us about developing new treatments.<\/p>\n Why does Nitrofurantoin work so well? Several factors contribute to its enduring effectiveness:<\/p>\n Nitrofurantoin\u2019s success can serve as a blueprint for designing new antibiotics that are robust against resistance. By combining targeted delivery, multifactorial action, and evolutionary barriers to resistance, future drugs can emulate nitrofurantoin\u2019s longevity.<\/p>\n However, despite its strengths, nitrofurantoin isn\u2019t invulnerable. The team also identified several risks to its ongoing efficacy. Emerging resistance linked to efflux pumps and mutation-prone \u201cmutator\u201d strains in clinical isolates highlights the importance of responsible usage and continued monitoring.<\/p>\n This perspective highlights the importance of patient adherence, cautious prophylactic use, and vigilant surveillance to safeguard nitrofurantoin\u2019s continued efficacy. Additionally, understanding and applying the principles underlying its durability could guide the development of future antibiotics, providing a strategic approach to combat antimicrobial resistance.<\/p>\n Read more at npj Antimicrobials and Resistance<\/a><\/em><\/p>\n<\/div>\n<\/div>\n\n
\n
\n